Status:
TERMINATED
Surgical Pulmonary Vein Isolation Efficiency Study
Lead Sponsor:
Kuopio University Hospital
Conditions:
Paroxysmal Atrial Fibrillation
Coronary Artery Disease
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
A substantial proportion of patients undergoing elective coronary artery bypass grafting have a history of paroxysmal atrial fibrillation. Paroxysmal atrial fibrillation has adverse short-and long ter...
Eligibility Criteria
Inclusion
- American College of Cardiology (ACC)/ American Heart Association (AHA) -Indications for CABG
- At least 2 ECG-verified (12-channel ECG, Holter telemetry) symptomatic paroxysmal atrial fibrillation episodes within last 12 months
- Duration of the atrial fibrillation episode must not exceed 1 week and it must reverse to sinus rhythm spontaneously or by cardioversion
- written and verbal consent
Exclusion
- Prior cardiac surgery
- Active pacemaker treatment
- Active anti-arrhythmic treatment(AAD) class I and III
- Contraindication to oral anticoagulant/heparin treatment
- Ejection fraction less than 30 % (EF \< 30 %)assessed by transthoracic echocardiography
- Left atrial diameter less than 55mm assessed by transthoracic echocardiography
- Renal insufficiency requiring dialysis
- Heart valve disease requiring invasive treatment
- Heart anomaly requiring regular controls and/or invasive treatment
Key Trial Info
Start Date :
November 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2020
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT01791218
Start Date
November 1 2012
End Date
September 1 2020
Last Update
September 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kuopio University Hospital
Kuopio, Eastern Finland, Finland, 70211